These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 23716559)

  • 21. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
    Leleu X; Attal M; Arnulf B; Moreau P; Traulle C; Marit G; Mathiot C; Petillon MO; Macro M; Roussel M; Pegourie B; Kolb B; Stoppa AM; Hennache B; Bréchignac S; Meuleman N; Thielemans B; Garderet L; Royer B; Hulin C; Benboubker L; Decaux O; Escoffre-Barbe M; Michallet M; Caillot D; Fermand JP; Avet-Loiseau H; Facon T;
    Blood; 2013 Mar; 121(11):1968-75. PubMed ID: 23319574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
    Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
    Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
    Lacy MQ; Allred JB; Gertz MA; Hayman SR; Short KD; Buadi F; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Stewart AK; Laumann K; Mandrekar SJ; Reeder C; Rajkumar SV; Mikhael JR
    Blood; 2011 Sep; 118(11):2970-5. PubMed ID: 21690557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
    Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
    Jagannath S; Richardson PG; Barlogie B; Berenson JR; Singhal S; Irwin D; Srkalovic G; Schenkein DP; Esseltine DL; Anderson KC;
    Haematologica; 2006 Jul; 91(7):929-34. PubMed ID: 16818280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.